Contagion Live

Contagion® serves as a comprehensive news platform dedicated to all aspects of infectious diseases. Our offerings include a website, a quarterly journal, email newsletters, social media updates, and the Outbreak Monitor. These resources deliver targeted information to healthcare professionals and specialists, aimed at enhancing patient care and aiding in the identification, diagnosis, treatment, and prevention of infectious diseases. Our goal is to empower both the healthcare community and the public with valuable knowledge, enabling better decision-making that positively influences patient outcomes.

International

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#344020

United States

#140556

Health/Health Conditions and Concerns

#337

Traffic sources

Monthly visitors

Articles

Evolving Challenges in C difficile Testing: Diagnostic Stewardship or Laboratory Retrogress?

1 week ago | contagionlive.com | Sophia Abene

Presented at ASM Microbe 2025, a process improvement project led by Navarathna et al at Central Texas Veterans Health Care System evaluated the impact of incorporating enzyme immunoassays (EIA) into existing PCR-based diagnostic protocols for Clostridioides difficile infection (CDI). The study compared two EIA platforms against PCR results and found that EIAs were less than 30% as sensitive as PCR.
Dual-Targeting miRNAs Identified as Potential Therapeutics Against HCV and BVDV

1 week ago | contagionlive.com | Sophia Abene

June 19, 2025Presented at ASM Microbe 2025, a bioinformatics study highlights nine human miRNAs capable of binding and potentially inhibiting both hepatitis C and bovine viral diarrhea viruses. Presented at ASM Microbe 2025, a bioinformatics-driven study has identified nine human microRNAs (miRNAs) with strong complementary binding to both hepatitis C virus (HCV) and bovine viral diarrhea virus (BVDV), supporting their potential use as targeted antiviral therapeutics.
FDA Approves Gilead’s Twice-Yearly Injectable Yeztugo (Lenacapavir) for HIV Prevention

1 week ago | contagionlive.com | Sophia Abene |Jared Baeten

Gilead Sciences, Inc announced today that the US Food and Drug Administration (FDA) has granted approval for lenacapavir, the company’s first-in-class, long-acting HIV-1 capsid inhibitor, for use as a twice-yearly pre-exposure prophylaxis (PrEP) to prevent HIV infection.
30% of Americans Express Vaccine Skepticism

1 week ago | contagionlive.com | Sophia Abene

A recent survey conducted by ValuePenguin involving over 2,000 US adults highlights a significant degree of vaccine skepticism in the general population, with implications for infectious disease management and public health efforts. Approximately 30% of respondents expressed doubts aligned with positions promoted by US Health Secretary Robert F Kennedy Jr, coinciding with a current measles outbreak and enduring safety concerns, including vaccine-autism misconceptions.
Psychiatric Symptoms Emerging Years After Infections Like Lyme and Tick-Borne Infections

1 week ago | contagionlive.com | Sophia Abene |Robert C Bransfield

For over 50 years, psychiatrist Robert C Bransfield, MD, has focused on treating patients with some of the most difficult psychiatric conditions, those resistant to conventional therapies. Over time, his clinical work led him to a surprising pattern: many of these patients had a history of infectious disease, particularly Lyme and other tick-borne illnesses. What he found challenges assumptions in both psychiatry and infectious disease.
Geographic And Demographic Variations in Hepatitis C Mortality

1 week ago | contagionlive.com | Sophia Abene

The 2023 CDC Hepatitis C Surveillance Report reveals important trends in hepatitis C-related mortality across the United States. Nationally, the hepatitis C-related death rate was 2.52 deaths per 100,000 population, marking a continuing decline from previous years. Although, this rate varied widely by state and demographic groups.1Among states, Oklahoma had the highest death rate, with 8.94 deaths per 100,000 population in 2023, significantly above the national average.
Merck Launches Phase 3 Trial of Single-Dose Dengue Vaccine Candidate V181

1 week ago | contagionlive.com | Sophia Abene

June 16, 2025Evaluating safety and efficacy against symptomatic, virologically confirmed dengue in children and adolescents. Merck has initiated MOBILIZE-1, the first phase 3 clinical trial of its investigational dengue vaccine candidate, V181, to evaluate its safety, immunogenicity, and efficacy in preventing dengue caused by all four virus serotypes, regardless of prior exposure.
Professional Societies Must Address Gaps When Politics Overrides Evidence

1 week ago | contagionlive.com | Jason Gallagher

With the ongoing current events related to vaccine policy, we decided to post this early release, of the Summer issue's Editor-in-Chief letter. “May you live in interesting times,” often cited incorrectly as a Chinese curse, is an idiom that has felt particularly apt of late. Our field faces new and significant challenges: grant cancellations, reduced support for infectious disease prevention and treatment, and the appointment of individuals without relevant expertise to key federal roles.
Deciphering Similarities and Differences in Antifungal and Antibiotic Development

1 week ago | contagionlive.com | John Parkinson |Jatin M Vyas

Globally, more than 6.5 million people contract fungal infections annually, according to a systematic review published last year in The Lancet Infectious Diseases.1 There are 3.8 million deaths with about 2.5 million of them directly attributable to these infections.1 The rise of these infections and consequently resistance can be contributed to factors such as the widespread use of fungicides in agriculture, climate change, fungal species’ ability to develop resistant mechanisms, and limited...
Top 5 Infectious Disease News Stories Week of June 7-June 14

2 weeks ago | contagionlive.com | Sophia Abene

The FDA has expanded approval of Moderna’s mRNA-1345 (mRESVIA) respiratory syncytial virus (RSV) vaccine to include adults aged 18 to 59 years, following its initial approval for those 60 and older to prevent lower respiratory tract disease caused by RSV. This decision was based on Moderna's phase 3 trial demonstrating that the vaccine elicited comparable immune responses in younger adults with underlying health conditions as seen in older adults, meeting non-inferiority criteria.